BioSpace News Archive

Pharm Country

ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference

ADMA Biologics, Inc. today announced that a poster presentation was made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference.

October 22, 2021
·
9 min read
Pharm Country

EY Smart Reviewer helps accelerate and optimize approval of marketing materials in the life sciences industry

EY today announces the launch of EY Smart Reviewer, a new technology-driven solution for the life sciences industry.

October 22, 2021
·
4 min read
Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting

Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie’s disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting.

October 22, 2021
·
11 min read
Pharm Country

Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis

LEO Pharma A/S today announced 16-week results of a 52-week monotherapy trial showing tralokinumab significantly improved primary and secondary measurements of efficacy among adolescents (aged 12 to 17) with moderate-to-severe atopic dermatitis.

October 22, 2021
·
6 min read
Drug Development

Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery of ceDNA and mRNA at the European Society of Gene and Cell Therapy 2021 Annual Virtual Congress

Generation Bio Co. today presented new preclinical data demonstrating widespread delivery of multiple nucleic acid cargos to photoreceptors using the company’s cell-targeted lipid nanoparticle (ctLNP).

October 22, 2021
·
5 min read
Drug Development

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

Athira Pharma, Inc. announced today that it has completed enrollment in ACT-AD , a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease.

October 22, 2021
·
7 min read